Skip to main content

689-05 A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA H

NCT03765918

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Associated Conditions

Head and Neck Cancer

Principal Investigator

Sponsor

Merck Sharp & Dohme

The purpose of this optional study is to test for biomarkers that help to understand the relationship between the study drug and your tumor.